{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:25:29Z","timestamp":1793298329796,"version":"4.5.0"},"reference-count":11,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:sec id=\"ab-hbr250024-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Among patients with heart failure with reduced ejection fraction (HFrEF) in US clinical practice, the residual risk of poor clinical outcomes despite quadruple medical therapy is not well characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr250024-2\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate clinical outcomes and health care costs among patients hospitalized for HFrEF prescribed quadruple medical therapy at discharge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr250024-3\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This retrospective cohort study examined Medicare beneficiaries hospitalized for HFrEF in the Get With The Guidelines\u2013Heart Failure registry and discharged from US hospitals receiving any dose of quadruple medical therapy (angiotensin receptor\u2013neprilysin inhibitor, \u03b2-blocker, mineralocorticoid receptor antagonist, and sodium-glucose cotransporter 2 inhibitor) between July 1, 2021, and December 31, 2023. Data analysis was conducted from October 2024 through March 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr250024-4\">\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>Prescription of quadruple medical therapy (angiotensin receptor\u2013neprilysin inhibitor, \u03b2-blocker, mineralocorticoid receptor antagonist, and sodium-glucose cotransporter 2 inhibitor) at time of hospital discharge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr250024-5\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcomes were mortality, HF hospitalization, mortality or HF hospitalization, and per-patient health care expenditure (Medicare Part A and B inpatient and outpatient costs, in 2023 US dollars).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr250024-6\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 20\u202f651 patients with HFrEF eligible for quadruple medical therapy across 532 US hospitals, 1490 (7.2%) were prescribed quadruple therapy at discharge, with high between-hospital variance (median odds ratio, 2.04; 95% CI, 1.89-2.24). Median (IQR) age of patients prescribed quadruple therapy was 74 (69-81) years, and 543 patients (36.4%) were women. Over 12-month follow-up, cumulative incidences of all-cause mortality, HF hospitalization, and all-cause mortality or HF hospitalization were 19.3% (95% CI, 17.3%-21.4%), 26.0% (95% CI, 23.6%-28.5%), and 37.1% (95% CI, 34.4%-39.8%), respectively. Median (IQR) 12-month per-patient health care expenditure was $27\u202f956 ($7478-$61\u202f126). Twelve-month mortality and HF hospitalization outcomes were similar for patients prescribed quadruple medical therapy at discharge in the first half vs the second half of the study period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr250024-7\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this nationwide cohort study, even when prescribed quadruple medical therapy, older patients hospitalized for HFrEF in US clinical practice face substantial residual risk of death and HF readmission and often accrue high health care costs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamacardio.2025.5339","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T16:31:25Z","timestamp":1769617885000},"page":"293","source":"Crossref","is-referenced-by-count":8,"title":["One-Year Outcomes in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Prescribed Quadruple Medical Therapy at Discharge"],"prefix":"10.1001","volume":"11","author":[{"given":"Stephen J.","family":"Greene","sequence":"first","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"},{"name":"Division of Cardiology, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haolin","family":"Xu","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Chiswell","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Michael","family":"Felker","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"},{"name":"Division of Cardiology, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabra C.","family":"Lewsey","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punag H.","family":"Divanji","sequence":"additional","affiliation":[{"name":"Cytokinetics, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Goertz","sequence":"additional","affiliation":[{"name":"Cytokinetics, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Heitner","sequence":"additional","affiliation":[{"name":"Cytokinetics, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanatan","family":"Shreay","sequence":"additional","affiliation":[{"name":"Cytokinetics, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambarish","family":"Pandey","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clyde W.","family":"Yancy","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois"},{"name":"Deputy Editor, JAMA Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Baylor Scott and White Research Institute, Dallas, Texas"},{"name":"Department of Medicine, University of Mississippi, Jackson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[{"name":"Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles"},{"name":"Associate Editor for Health Care Quality and Guidelines, JAMA Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"17","key":"hbr250024r1","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"hbr250024r2","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"8","key":"hbr250024r3","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1001\/jamacardio.2020.0898","article-title":"Association of optimal implementation of sodium-glucose cotransporter 2 inhibitor therapy with outcome for patients with heart failure.","volume":"5","author":"Bassi","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"5","key":"hbr250024r4","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1016\/j.ahj.2004.09.015","article-title":"The American Heart Association Get With The Guidelines program.","volume":"148","author":"Smaha","year":"2004","journal-title":"Am Heart J"},{"issue":"10","key":"hbr250024r5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.125.012936","article-title":"Get With The Guidelines-Heart Failure: twenty years in review, lessons learned, and the road ahead.","volume":"18","author":"Tang","year":"2025","journal-title":"Circ Heart Fail"},{"issue":"6","key":"hbr250024r6","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.ahj.2009.04.002","article-title":"Linking inpatient clinical registry data to Medicare claims data using indirect identifiers.","volume":"157","author":"Hammill","year":"2009","journal-title":"Am Heart J"},{"issue":"8","key":"hbr250024r7","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.jchf.2024.03.001","article-title":"Eligibility and projected benefits of rapid initiation of quadruple therapy for newly diagnosed heart failure.","volume":"12","author":"Greene","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"1","key":"hbr250024r8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.012357","article-title":"Social determinants of health and disparities in guideline-directed medical therapy optimization for heart failure.","volume":"18","author":"Jacobs","year":"2025","journal-title":"Circ Heart Fail"},{"issue":"22","key":"hbr250024r10","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1001\/jama.2021.20739","article-title":"Contextualizing risk among patients with heart failure.","volume":"326","author":"Greene","year":"2021","journal-title":"JAMA"},{"issue":"9","key":"hbr250024r11","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/ejhf.822","article-title":"Do patients have worse outcomes in heart failure than in cancer? a primary care-based cohort study with 10-year follow-up in Scotland.","volume":"19","author":"Mamas","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"hbr250024r9","unstructured":"Market basket data. US Centers for Medicare & Medicaid Services. Accessed September 18, 2023. https:\/\/www.cms.gov\/data-research\/statistics-trends-and-reports\/medicare-program-rates-statistics\/market-basket-data"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2844102\/jamacardiology_greene_2026_br_250024_1773061344.40795.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T15:01:02Z","timestamp":1773241262000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2844102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2025.5339","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}